Free tool
FAERS Monitor: Proleukin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103293 or its brand name (Proleukin, Aldesleukin). Reports on generic versions are filed under their own applications.
Reports
1,262
Serious
1,172
93% of reports
Hospitalization
612
Death reported
211
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia153
- hypotension112
- off label use107
- thrombocytopenia84
- diarrhoea82
- vomiting71
- nausea69
- fatigue67
- chills65
- dyspnoea65
- febrile neutropenia64
- pain62
- hypoxia56
- drug ineffective55
- disease progression53
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 92 |
| 2005 | 103 |
| 2006 | 48 |
| 2007 | 54 |
| 2008 | 55 |
| 2009 | 41 |
| 2010 | 42 |
| 2011 | 49 |
| 2012 | 35 |
| 2013 | 28 |
| 2014 | 12 |
| 2015 | 20 |
| 2016 | 24 |
| 2017 | 51 |
| 2018 | 12 |
| 2019 | 41 |
| 2020 | 68 |
| 2021 | 72 |
| 2022 | 44 |
| 2023 | 56 |
| 2024 | 111 |
| 2025 | 130 |
| 2026 | 74 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,897 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoxiaSignal | 56 | 26.5 | 20.5 | 1,351 |
| febrile neutropeniaSignal | 64 | 16.1 | 12.7 | 893 |
| thrombocytopeniaSignal | 84 | 12.5 | 10.2 | 884 |
| hypotensionSignal | 112 | 9.3 | 7.8 | 830 |
| chillsSignal | 65 | 9.2 | 7.3 | 472 |
| disease progressionSignal | 53 | 7.5 | 5.7 | 292 |
| pyrexiaSignal | 153 | 7.4 | 6.4 | 850 |
| vomitingSignal | 71 | 2.5 | 2.0 | 65 |
| diarrhoeaSignal | 82 | 2.1 | 1.7 | 49 |
| off label useSignal | 107 | 2.0 | 1.7 | 58 |
| dyspnoea | 65 | 1.9 | 1.5 | 28 |
| pain | 62 | 1.7 | 1.3 | 17 |
| nausea | 69 | 1.5 | 1.2 | 10 |
| fatigue | 67 | 1.4 | 1.1 | 9 |
| drug ineffective | 55 | 0.7 | 0.5 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.